Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director | June 21, 2026 | June 23, 2026 |
| Verona Pharma plcVRNA · Entity 74409 | Director | August 09, 2021 | August 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 21, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-20 | Direct | 4,200 |
Reported balance
After 2026-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-21 · Grant · Acquired 4,200 · Balance 4,200 F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Verona Pharma plc
Report date August 09, 2021 · Filed August 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.78 · Expires 2031-08-08 | Direct | 64,000 |
Reported balance
After 2021-08-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-09 · Grant · Acquired 64,000 · Balance 64,000 F1: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: The option vests and becomes exercisable as to 25% on August 9, 2021, 25% on November 1, 2021, 25% on February 1, 2022 and 25% on May 1, 2022.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 10,491 · Balance 0 F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.55 · Expires 2028-12-21 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 1,333 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2029-06-10 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Disposition to issuer · Disposed 823 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.15 · Expires 2030-05-18 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-18 · Disposition to issuer · Disposed 635 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.60 · Expires 2031-01-08 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.30 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-18 · Disposition to issuer · Disposed 2,124 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2032-06-01 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-18 · Disposition to issuer · Disposed 2,666 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25 · Expires 2033-05-26 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-18 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 1,314,127 · Balance 0 F3: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 12, 2022 (the "Merger Agreement"), between Sierra Oncology Inc. (the "Issuer"), GlaxoSmithKline plc ("GSK"), and Orikum Acquisition Inc. ("Acquisition Sub"). On July 1, 2022, upon the closing of the merger of Acquisition Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $55.00, without interest and less any applicable withholding taxes. F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2029-11-29 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 1,500 · Balance 0 F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F6: The option vested in equal monthly installments over a period of 12 months commencing on December 29, 2019, and was fully vested at the effective time of the Merger. F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 6,874 · Balance 0 F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F7: The option vested as to 8.333% of the total shares monthly, commencing on July 9, 2020, and was fully vested at the effective time of the Merger. F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2031-06-08 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 6,000 · Balance 0 F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series A Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.20 · Expires 2024-11-13 | IndirectSee footnotes | 0 |
Reported balance
After 2022-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-01 · Disposition to issuer · Disposed 871,125 · Balance 0 F9: At the effective time of the Merger, each warrant to purchase common stock of the Issuer (the "Series A warrants") that was outstanding as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to $45.98 per share of the Issuer's common stock subject to the Series A warrants. F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP.
F2: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.
F3: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 12, 2022 (the "Merger Agreement"), between Sierra Oncology Inc. (the "Issuer"), GlaxoSmithKline plc ("GSK"), and Orikum Acquisition Inc. ("Acquisition Sub"). On July 1, 2022, upon the closing of the merger of Acquisition Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $55.00, without interest and less any applicable withholding taxes.
F4: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP.
F5: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F6: The option vested in equal monthly installments over a period of 12 months commencing on December 29, 2019, and was fully vested at the effective time of the Merger.
F7: The option vested as to 8.333% of the total shares monthly, commencing on July 9, 2020, and was fully vested at the effective time of the Merger.
F8: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option.
F9: At the effective time of the Merger, each warrant to purchase common stock of the Issuer (the "Series A warrants") that was outstanding as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to $45.98 per share of the Issuer's common stock subject to the Series A warrants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2026 Filed Jun 23, 2026 20:27 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001762451-26-000002 · ownership.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 Underlying: Common Stock · 4,200 shares Expires 2036-06-20 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 10,000 | Not disclosed Strike: $5.25 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 9 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-05-26 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,666 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 8 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,666 shares Expires 2033-05-25 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,666 | Not disclosed Strike: $2.55 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 7 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,666 shares Expires 2032-06-01 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,124 | Not disclosed Strike: $15.30 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 6 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,124 shares Expires 2031-06-01 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 2,666 | Not disclosed Strike: $33.60 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 5 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,666 shares Expires 2031-01-08 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 635 | Not disclosed Strike: $51.15 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 4 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 635 shares Expires 2030-05-18 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 823 | Not disclosed Strike: $39.45 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 3 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 823 shares Expires 2029-06-10 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 1,333 | Not disclosed Strike: $23.55 | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,333 shares Expires 2028-12-21 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:47 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerCommon Stock | 10,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001762451-26-000001 · form4-05182026_080529.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Certain of these shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2 · price: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:04 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-086135 · ownership.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2035-06-10 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:04 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086135 · ownership.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,700 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 23:25 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 3,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-016360 · form4-06092025_110614.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,491 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 5, 2025 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F2 · balance_after: Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 10 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 9 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 8 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 7 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 8,172 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 6 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,172 Underlying: Common Stock · 8,172 shares Expires 2031-04-29 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,172 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 5 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,172 shares Expires 2031-04-29 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 4 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 3 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 28,828 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,828 Underlying: Common Stock · 28,828 shares Expires 2031-03-01 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:08 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,828 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100180 · ownership.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,828 shares Expires 2031-03-01 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| June 06, 2024 Filed Jun 11, 2024 00:51 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016311 · form4-06112024_120646.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. F1 · balance_after: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest on the earlier of the twelve-month anniversary of June 6, 2024 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:03 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0000950170-24-070575 · ownership.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2034-06-04 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:03 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070575 · ownership.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,800 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 10 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 9 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 8 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 7 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 8,172 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 6 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,172 Underlying: Common Stock · 8,172 shares Expires 2031-04-29 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on March 2, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,172 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 5 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,172 shares Expires 2031-04-29 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on March 2, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 4 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $15.93 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 3 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires 2031-04-29 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 28,828 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,828 Underlying: Common Stock · 28,828 shares Expires 2031-03-01 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: 33% of the shares subject to this option vested and became exercisable on March 2, 2022, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,828 | $0.00 Strike: $15.75 | $0.00 |
DisclosureSEC source: 0001209191-23-046096 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,828 shares Expires 2031-03-01 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: 33% of the shares subject to this option vested and became exercisable on March 2, 2022, with the remaining 67% vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:46 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $5.20 | $0.00 |
DisclosureSEC source: 0001209191-23-033955 · doc4.xml · derivative · entry 3 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-31 F4 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:46 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033955 · doc4.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| May 26, 2023 Filed May 26, 2023 22:30 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001209191-23-032697 · doc4.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares subject to the Option shall vest on November 26, 2023, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 22:30 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 2,666 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-23-032697 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2033-05-25 F1 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of May 25, 2023 or the day before the next annual stockholder meeting, subject to the Reporting Person continuing to be a Service Provider through such date. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 20:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerSeries A Warrants (Right to Buy) · Derivative | 871,125 | $45.98 Strike: $13.20 | $40,054,327.50 |
DisclosureSEC source: 0001493152-22-018397 · ownership.xml · derivative · entry 5 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 871,125 shares Expires 2024-11-13 F9 · price: At the effective time of the Merger, each warrant to purchase common stock of the Issuer (the "Series A warrants") that was outstanding as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to $45.98 per share of the Issuer's common stock subject to the Series A warrants. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 20:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed Strike: $18.11 | Not disclosed |
DisclosureSEC source: 0001493152-22-018397 · ownership.xml · derivative · entry 4 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F8 · price: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F4 · ownership.direct: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5 · ownership.direct: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 20:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,874 | Not disclosed Strike: $13.98 | Not disclosed |
DisclosureSEC source: 0001493152-22-018397 · ownership.xml · derivative · entry 3 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,874 shares Expires 2030-06-09 F8 · price: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F7 · derivative.exercise_date: The option vested as to 8.333% of the total shares monthly, commencing on July 9, 2020, and was fully vested at the effective time of the Merger. F4 · ownership.direct: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5 · ownership.direct: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 20:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,500 | Not disclosed Strike: $13.87 | Not disclosed |
DisclosureSEC source: 0001493152-22-018397 · ownership.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2029-11-29 F8 · price: Pursuant to the Merger Agreement, at the effective time of the Merger all options that were outstanding and unexercised as of immediately prior to the effective time of the Merger accelerated vesting in full and were cancelled and converted into a right to receive an amount in cash, without interest, equal to the product of (1) the excess, if any, of $55.00 less the exercise price per share of such option, and (2) the number of shares of the Issuer's common stock issuable upon exercise in full of such option. F6 · derivative.exercise_date: The option vested in equal monthly installments over a period of 12 months commencing on December 29, 2019, and was fully vested at the effective time of the Merger. F4 · ownership.direct: This option was granted to Dr. Andrew Sinclair as director's compensation. Dr. Sinclair is a Partner of Abingworth LLP. Under an agreement between Dr. Sinclair and Abingworth LLP, Dr. Sinclair is deemed to hold the options and any shares of Common Stock issuable upon exercise of the options for the benefit of ABV VII, and must exercise the options solely upon the direction of Abingworth LLP. F5 · ownership.direct: ABV VII may be deemed the indirect beneficial owner of the option, and Dr. Sinclair may be deemed the indirect beneficial owner of the option through his indirect interest in ABV VII. Abingworth LLP disclaims beneficial ownership of the option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV VII, Dr. Sinclair or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 20:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerCommon Stock, $0.001 par value | 1,314,127 | $55.00 | $72,276,985.00 |
DisclosureSEC source: 0001493152-22-018397 · ownership.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 F3 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 12, 2022 (the "Merger Agreement"), between Sierra Oncology Inc. (the "Issuer"), GlaxoSmithKline plc ("GSK"), and Orikum Acquisition Inc. ("Acquisition Sub"). On July 1, 2022, upon the closing of the merger of Acquisition Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each share of common stock of the Issuer, par value $0.001 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $55.00, without interest and less any applicable withholding taxes. F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:41 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001209191-22-034097 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 01, 2022 Filed Oct 14, 2022 22:31 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantStock option (right to buy) · Derivative | 2,666 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-22-053698 · doc4.xml · derivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666 Underlying: Common Stock · 2,666 shares Expires 2032-06-01 F1 · derivative.exercise_price: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F2 · derivative.exercise_date: The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date. F1 · derivative.underlying_shares: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. F1 · balance_after: The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 21:29 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseWarrant (right to buy) · Derivative | 7,720,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0000905718-22-000521 · solenoth_fm4mar292022.xml · derivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 7,720,000 Underlying: Common Stock · 7,720,000 shares Expires 2027-03-29 F3 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F1 · ownership.nature: The securities of Soleno Therapeutics, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 21:29 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | PurchaseCommon Stock | 7,720,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-22-000521 · solenoth_fm4mar292022.xml · nonDerivative · entry 1 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 18,022,602 F3 · price: Each share of common stock was purchased together with one (1) warrant to purchase one (1) share of common stock for an aggregate price of $0.25. F1 · ownership.nature: The securities of Soleno Therapeutics, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 22:04 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | PurchaseCommon Stock, $0.001 par value | 150,000 | $27.00 | $4,050,000.00 |
DisclosureSEC source: 0000905718-22-000178 · sierraonco_fm4jan282022.xml · nonDerivative · entry 2 Sinclair Andrew · CIK 0001762451 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 1,314,127 F1 · ownership.nature: The securities of Sierra Oncology, Inc. (the "Issuer") are held by Abingworth Bioventures VII, LP ("ABV VII"). Abingworth LLP is the investment manager of ABV VII and has been delegated with all investment and dispositive power over the securities held by ABV VII. Reporting Person is a Partner and Portfolio Manager of Abingworth LLP. F2 · ownership.nature: An investment committee approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VII. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VII to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.